Brugger W, Scheding S, Bock T, Ziegler B, Kanz L
Department of Hematology, Oncology and Immunology, University of Tübingen, Germany.
Stem Cells. 1997;15 Suppl 1:159-65. doi: 10.1002/stem.5530150820.
Clinical success of autologous peripheral blood progenitor cell (PBPC) transplantation is challenged by relapse of malignant disease which might at least in part be mediated by graft-contaminating tumor cells. Although the clinical efficacy of tumor cell depletion still remains to be demonstrated, multiple purging strategies are currently pursued in the context of autologous stem cell transplantation. This report discusses ex vivo manipulations of PBPC transplants with respect to purging of tumor cells, including positive selection of CD34+ cells with or without negative depletion of tumor cells as well as ex vivo expansion techniques. Moreover, strategies with an adoptive immunotherapy using ex vivo-generated autologous dendritic cells for the treatment of minimal residual disease after stem cell transplantation will be discussed here.
自体外周血祖细胞（PBPC）移植的临床成功受到恶性疾病复发的挑战，而恶性疾病复发可能至少部分是由污染移植物的肿瘤细胞介导的。尽管肿瘤细胞清除的临床疗效仍有待证实，但目前在自体干细胞移植的背景下正在探索多种清除策略。本报告讨论了PBPC移植在肿瘤细胞清除方面的体外操作，包括对CD34+细胞进行阳性选择，同时或不同时对肿瘤细胞进行阴性清除，以及体外扩增技术。此外，本文还将讨论采用体外生成的自体树突状细胞进行过继性免疫治疗以治疗干细胞移植后微小残留病的策略。
